Skip to main content
SpringerLink
Log in

Immunohistochemical Markers for Prognosis of Anaplastic Astrocytomas

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Among the entire spectrum of astrocytic neoplasms, just anaplastic astrocytoma (or grade III astrocytoma) appears to be a more enigmatic tumor entity with vague criteria for pathological diagnosis, unclear biological behavior and diverse clinical outcome. Attempts have been made to identify biological markers that would be useful in prediction of prognosis of anaplastic astrocytomas but the results obtained are controversial. In the present study, survival data on 63 patients with anaplastic astrocytoma were studied to evaluate a possible association between clinical outcome and expression of some immunohistochemical variables. Both the progression-free (PFS) and overall (OS) survival times were significantly reduced for patients older than 45 years, for anaplastic astrocytomas containing multiple mitoses, for Ki-67 LI > 5%, for cyclin A LI > 4% and for PTEN-negative tumors. We found no differences in survival times in patients with or without p53 immunoreactivity and also in cases with different values of p16 and p27 immunostaining. Multivariate analysis revealed that risk of tumor progression and death is independently associated with tumors containing multiple mitoses and for PTEN-negative tumors. According to the data from the CART modeling, tumors were subdivided based on the three following subsets: (1) Anaplastic astrocytomas with solitary mitosis. (2) Anaplastic astrocytomas with multiple mitoses and PTEN positivity. (3) Anaplastic astrocytomas with multiple mitoses and PTEN negativity. Thus, the results obtained reveal the advantage of combined approach including evaluation of routine histological parameters and immunohistochemical variables for further clinical subdivision of anaplastic astrocytomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM: Tumors of central neuroepithelial origin. In: Bigner DD, McLendon RE, Bruner JM (eds) Russel and Rubinstein's Pathology of Tumors of the Nervous System. vol 1, 6th edn. Arnold, London, 1998, pp 387-417

    Google Scholar 

  2. Kleihues P, Cavenee WK: Tumors of the Nervous System. Pathology and Genetics: World Health Organization International Classification of Tumours. IARC press, Lyon, 2000, pp 27-28

    Google Scholar 

  3. Fischbach AJ, Martz KL, Nelson JS, Griffin TW, Cahng CH, Horton J: Long-term survival in treated anaplastic astrocytomas. A report of combined RTOG/ECOG studies. Am J Clin Oncol 14: 365-370, 1991

    Google Scholar 

  4. Hess KR: Extent of resection as a prognostic variable in the treatment gliomas. J Neuro-Oncol 42: 227-231, 1999

    Google Scholar 

  5. Salcman M, Scholtz H, Kaplan RS, Kulik S: Long-term survival in patients with malignant astrocytoma. Neurosurgery 34: 213-220, 1994

    Google Scholar 

  6. Schuurman PR, Troost D, Verbeeten B Jr, Bosch DA: Five-year survival and clinical prognostic factors in progressive supratentorial diffuse ‘low-grade’ astrocytoma: a retrospective analysis of 46 cases. Acta Neurochir 139: 2-7, 1997

    Google Scholar 

  7. Daumas-Duport C, Scheithauer BW, O'Fallon J, Kelly P: Grading of astrocytomas: a simple and reproducible method. Cancer 62: 2152-2165, 1988

    Google Scholar 

  8. Cohadon F, Aouad N, Rougier A, Vital C, Rivel J, Dartigues JF: Histologic and non-histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neuro-Oncol 3: 105-111, 1995

    Google Scholar 

  9. Coons SW, Johnson PC, Scheithauer BW, Yates AI, Pearl DK: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79: 1381-1393, 1997

    Google Scholar 

  10. Coons SW, Pearl DK: Mitosis identification in diffuse gliomas. Implication for tumor grading. Cancer 82: 1550-1555, 1998

    Google Scholar 

  11. Perry A, Jenkins RB, O'Fallon JR, Schaefer PL, Kimmel DW, Mahoney MR, Scheithauer BW, Smith SM, Hill EM, Sebo TJ, Levitt R, Krook J, Tschetter LK, Morton RF, Buckner JC: Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 86: 672-683, 1999

    Google Scholar 

  12. Sallinen PK, Sallinen SL, Hele PT, Rantala IS, Rautiainen E, Helin HJ, Kalimo H, Haapasalo HK: Grading of diffusely infiltrating astrocytomas by quantitative histopathology, cell proliferation and image cytometric DNA analysis. Comparison of 133 tumours in the context of the WHO 1979 and WHO 1993 grading schemes. Neuropathol Appl Neurobiol 26: 319-331, 2000

    Google Scholar 

  13. Shaw EG, Scheithauer BW, O'Fallon JR: Supratentorial gliomas: a comparative study by garde and histological type. J Neuro-Oncol 31: 273-278, 1997

    Google Scholar 

  14. Al-Sarraj S, Bridges LR: p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 9: 143-149, 1995

    Google Scholar 

  15. Ang LC, Plewes M, Tan L, Begley H, Agranovich A, Shul D: Proliferating cell nuclear antigen expression in the survival of astrocytoma patients. Can J Neurol Sci 21: 306-310, 1994

    Google Scholar 

  16. Chozick BS, Pezullo JC, Epstein MH, Finch PW: Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35: 831-838, 1994

    Google Scholar 

  17. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB: Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 86: 121-130, 1997

    Google Scholar 

  18. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH: Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery 37: 246-264, 1997

    Google Scholar 

  19. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry 59: 413-419, 1995

    Google Scholar 

  20. Ehrmann JJ, Kolar Z, Vojtesek B, Kala M, Komenda S, Oulto A: Prognostic factors in astrocytomas: relationship of p53, MDM2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma 44: 299-304, 1997

    Google Scholar 

  21. Ganju V, Jenkins RB, O'Fallon JR, Scheithauer BW, Ransom DT, Katzmann JA, Kimmel DA: Prognostic factors in gliomas. A multivariate analysis of clinical pathological, flow cytometric, cytogenetic, and molecular markers. Cancer 74: 920-927, 1994

    Google Scholar 

  22. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ: Cellular proliferation in pilocytic and diffuse astrocytomas: an MIB-1 labeling index study. J Neuropathol Exp Neurol 58: 46-53, 1999

    Google Scholar 

  23. Hara A, Saegusa M, Mikami T, Okayasu I: Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. J Clin Pathol 54: 860-865, 2001

    Google Scholar 

  24. Heesters MAAM, Koudstaal J, Go KG, Molenaar WM: Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neuro-Oncol 44: 255-266, 1999

    Google Scholar 

  25. Hiura T, Khalid H, Yamashita H, Tokunaga Y, Yasunaga A, Shibata S: Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Cancer 83: 2361-2369, 1998

    Google Scholar 

  26. Holden JA, Townsend JJ: DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 12: 1094-1100, 1999

    Google Scholar 

  27. Hsu D, Louis DN, Efird JT, Hedley-White ET: Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 56: 857-865, 1997

    Google Scholar 

  28. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag AM: Prognostic implication of p53 protein, epidermal growth factor receptor and Ki-67 labelling in brain tumor. Br J Cancer 66: 373-385, 1992

    Google Scholar 

  29. Kirkegaard LJ, DeRose PB, Yao B, Cohen C: Image cytometric measurement of nuclear prliferative markers (MIB-1, 214 PCNA) in astrocytomas. Prognostic significance. Am J Clin Pathol 109: 69-74, 1998

    Google Scholar 

  30. Kirla R, Salminen E, Huhtala S, Nuutinen J, Talve L, Haapasalo H, Kalimo H: Prognostic value of the expression of tumor suppressor genes p53, p21, p16, and pRb, and Ki-67 labelling in high-grade astrocytomas treated with radiotherapy. J Neuro-Oncol 46: 71-80, 2000

    Google Scholar 

  31. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferating markers and epidermal growth factors receptor. Br J Cancer 75: 1269-1278, 1997

    Google Scholar 

  32. Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinogen 15: 14-18, 1996

    Google Scholar 

  33. Leenstra S, Oskam NT, Bijleveld EH, Bosch DA, Troost D, Hulsebos TJ: Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 79: 159-165, 1998

    Google Scholar 

  34. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA: Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001

    Google Scholar 

  35. Mastronardi L, Guiddici A, Pizzulli F, Ruggeri A: Relationship between Ki-67 labeling index and survival in high-grade glioma patients treated after surgery with tamoxifen. J Neurosurg Sci 43: 263-270, 1999

    Google Scholar 

  36. McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L: A comparison of the predictive power for survival in gliomas provided by MIB-1, bromdeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 56: 798-805, 1997

    Google Scholar 

  37. Miettinen H, Kononen J, Sallinen P, Alho H, Helen P, Helin H, Kalimo H, Paljarvi L, Isola J, Haapasalo H: CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neuro-Oncol 41: 205-211, 1999

    Google Scholar 

  38. Montine TJ, Bruner JM, Vandersteenhoven JJ, Dodge RK, Burger PC: Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn Mol Pathol 3: 240-254, 1994

    Google Scholar 

  39. Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, Dodge RK, Kerns B: Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 34: 674-679, 1994

    Google Scholar 

  40. Nakamura M, Konishi M, Tsunoda S, Hiasa Y, Tsuzuki T, Inui T, Sasaki T: Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 80: 242-249, 1997

    Google Scholar 

  41. Nieder C, Petersen S, Petersen C, Thames HD: The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 26: 67-73, 2000

    Google Scholar 

  42. Puduvalli VK, Kyristis AP, Hess KR, Bondy ML, Fuller GN, Kouraklis GP, Levin VA, Bruner JM: Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol 17: 963-969, 2000

    Google Scholar 

  43. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschläger C, Heidecke V, Burkert W: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-Oncol 35: 13-28, 1997

    Google Scholar 

  44. Ricco R, Cimmino A, Renzulli G, Serio G, Lozupone A, Lettini T, Pece A, Giardina C, Delfino VP: Real-time quantification of the proliferative state in astrocytomas. Ann Quant Cytol Histol 22: 213-217, 2000

    Google Scholar 

  45. Rodriguez-Pereira C, Suarez-Peneranda JM, Barros F, Sobrido MJ, Vazquez-Salvado M, Fortez J: Analysis of 2 antiapoptotic factors in gliomas. bcl-2 overexpression and p53 mutation. Arch Pathol Lab Med 125: 218-223, 2001

    Google Scholar 

  46. Sallinen PK, Haapasalo HK, Visakorpi T, Helin PT, Rantala IS: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275-282, 1994

    Google Scholar 

  47. Smith JS, Jenkins RB: Genetic alteration in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 5: D213-231, 2000

    Google Scholar 

  48. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB: PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001

    Google Scholar 

  49. Soini Y, Nyemela A, Kamel D, Herva R, Bloigu R, Pekki P: p53 immunohistichemcial positivity as a prognostic marker in intracranial tumours. APMIS 102: 786-792, 1993

    Google Scholar 

  50. Taniguchi K, Wakabayashi T, Yoshida T: Immunohistochemical staining of DNA topoisomerase II a in human gliomas. J Neurosurg 91: 477-482, 1999

    Google Scholar 

  51. Theunissen PHMH, Blaauw J: Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytomas. Histopathology 23: 75-79, 1993

    Google Scholar 

  52. Korshunov A, Golanov A, Sycheva R, Pronin I: Prognostic value of tumour-associated antigens immunoreactivity and apoptosis in cerebral glioblastomas: An analysis of 168 cases. J Clin Pathol 52: 574-580, 1999

    Google Scholar 

  53. Germano IM, Ito M, Cho KG, Hoshino S, Davis RL, Wilson CB: Correlation of histopathological features and proliferative potential of gliomas. J Neurosurg 70: 701-706, 1989.

    Google Scholar 

  54. Allan K, Jordan RCK, Ang LC, Taylor M, Young B: Overexpression of cyclin A and cyclin B1 proteins in astrocytomas. Arch Pathol Lab Med 124: 216-220, 2000

    Google Scholar 

  55. Chakrabarty A, Bridges LR: Immunohistochemical analysis of cyclin A in astrocytic tumors. Neuropathol Appl Neurobiol 24: 239-245, 1998

    Google Scholar 

  56. Ren Y, Munyer P, Kepes JJ: Comparison of cyclin A and MIB-1 expression in astrocytic tumors using image-based cell analysis system. Appl Immunohist Mol Morphol 9: 14-18, 2001

    Google Scholar 

  57. Tamiya T, Mizumatsu S, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: High cyclin E/low p27kip1 expression is associated with poor prognosis in astrocytomas. Acta Neuropathol (Berl) 101: 334-340, 2001

    Google Scholar 

  58. Ali IU, Schriml LM, Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932, 1999

    Google Scholar 

  59. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner SH, Bigner DD: PTEN gene mutation are seen in high-grade but not in low-grade gliomas. Cancer Res 57: 4187-4190, 1997

    Google Scholar 

  60. Zhou XP, Li YJ, Hoang-Xuan K, Lauren-Puig P, Mokhtari K, Longy M: Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 84: 150-154, 1999

    Google Scholar 

  61. Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X: Allelic deletion analysis of MMAC/PTEN and DMBT1 loci in gliomas. Relationship to prognostic significance. Clin Cancer Res 4: 2447-2454, 1998

    Google Scholar 

  62. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WKA, Steck PA: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59: 1820-1824, 1999

    Google Scholar 

  63. Raffel C, Frederiick L, O'Fallon JR, Atherton-Skaff P, Perry A, Jenkins RB, James CD: Analysis of oncogene and tumor suppressor gene alteration in pediatric malignant astrocytomas reduced survival for patients with PTEN mutation. Clin Cancer Res 5: 4085-4090, 1999

    Google Scholar 

  64. Tada K, Shiraishi S, Kamiryo T, Nakamura H, Hirano H, Kuratsu J, Kochi M, Saya H, Ushio Y: Analysis of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg 95: 651-659, 2001

    Google Scholar 

  65. Fults D, Pedone C: Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas. Neuro-Oncology 2: 71-79, 2000

    Google Scholar 

  66. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Lois DN: Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferative indices. J Neuropathol Exp Neurol 55: 1026-1031, 1996

    Google Scholar 

  67. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW: p27kip1: multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154: 313-323, 1999

    Google Scholar 

  68. Alleyne GH Jr, He J, Yang J, Hunter SB, Cotsonis G, James CD, Olson JJ: Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol 14: 1111-1116, 1999

    Google Scholar 

  69. Fuse T, Tanikawa M, Nakanishi M: p27Kip1 expression by contact inhibition as a prognostic index of human glioma. J Neurochem 74: 1393-1399, 2000

    Google Scholar 

  70. Mizumatsu S, Tamiya T, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: Expression of cell cycle regulator p27kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res 5: 551-557, 1999

    Google Scholar 

  71. Piva R, Cavalla S, Bortolotto S, Cordera S, Richiardi P, Schiffer D: p27/kip1 expression in human astrocytic gliomas. Neurosci Lett 234: 127-130, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropathology, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Andrey Korshunov & Regina Sycheva

  2. Department of Neuro-Oncological Surgery, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Andrey Golanov

Authors
  1. Andrey Korshunov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrey Golanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Regina Sycheva
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korshunov, A., Golanov, A. & Sycheva, R. Immunohistochemical Markers for Prognosis of Anaplastic Astrocytomas. J Neurooncol 58, 203–215 (2002). https://doi.org/10.1023/A:1016261900413

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016261900413

Search

Navigation